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The tumor promoter okadaic acid binds specifically to a particulate as well as a cytosolic fraction of various mouse 
tissues, e.g., skin, brain, lung and colon. The Ko value was 21.7 nM for receptors in the particulate fraction and 1 .O 
nM for those in the cytosolic fraction of mouse skin. The specific binding of PH]okadaic acid to the particulate fraction 
of mouse skin was inhibited dosedependently by okadaic acid, but not okaidaic acid tetramethyl ether, an inactive com- 
pound, or by other tumor promoters, such as 12-0-tetradecanoylphorbol-13-acetate and teleocidin. The results suggest 
a new pathway of tumor promotion mediated through the okadaic acid receptor(s). 
Okadaic acid; Tumor promoter; Specific binding 
1. INTRODUCTION 
Okadaic acid, which is a polyether compound of 
a C3s fatty acid isolated from a black sponge Hali- 
chondria okadai [l], showed potent tumor- 
promoting activity in a two-stage carcinogenesis 
experiment on mouse skin [2]. The tumor- 
promoting activity of okadaic acid is as strong as 
that of teleocidin, but these two tumor promoters 
act on the cells in different ways. Namely, okadaic 
acid does not inhibit the specific binding of 
[3H] 12-O-tetradecanoylphorbol-13-acetate (TPA) 
to a particulate fraction of mouse skin, or activate 
protein kinase C isolated from mouse brain in 
vitro, whereas teleocidin, like TPA and aplysiatox- 
in, does both [2,3]. We are studying this new path- 
way for tumor promotion with okadaic acid. 
Recently, we obtained [27-3H]okadaic acid by 
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tritium-labeling of methyl 27-ketookadaate with 
sodium boro[3H]hydride [4]. In this paper, we 
report the specific binding of [‘Hlokadaic acid to 
both a particulate fraction and a cytosolic fraction 
of mouse skin. DEAlScellulose column 
chromatography of the cytosolic fraction of mouse 
skin gave a protein peak, eluted with 0.2 M NaCl, 
that also showed significant specific binding of 
[3H]okadaic acid. The binding fraction of mouse 
skin contained protein phosphatases and protein 
kinases (data not shown). Similar results have also 
been found in mouse brain (51. The specific binding 
of [3H]okadaic acid is intimately associated with 
protein phosphatase activity. The results indicate a 
new mechanism of action of the tumor promoter, 
okadaic acid. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Okadaic acid and dinophysistoxin-1 (3Smethylokadaic acid) 
were isolated from a black sponge, Halichondria okadai as 
described previously [1,2,6]. Okadaic acid tetramethyl ether was 
synthesized chemically from okadaic acid [7]. [27-‘H]Okadaic 
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acid (14 Ci/mmol) was prepared at Amersham (Buckingham- 
shire, England) as reported previously [4]. 
2.2. Specific binding of [3H]okadaic acid 
Particulate and cytosolic fractions from the epidermis of the 
back of CD-l mice were prepared as described previously [8]. 
Specific binding of [‘Hlokadaic acid to a particulate fraction 
was measured by the filtration method that follows. [‘HI- 
Okadaic acid was incubated with the particulate fraction in a 
total volume of 1 ml of 50 mM Tris-HCl buffer, pH 7.4, con- 
taining 2 mM 2-mercaptoethanol for 20 min at 37°C. Then the 
mixture was filtered on a GF/F glass fiber filter with 50 mM 
Tris-HCl buffer, pH 7.4, containing bovine serum albumin at a 
concentration of 1 mg/ml. Specific binding of [‘Hlokadaic acid 
to the cytosolic fraction was assayed by the filtration method 
using cold acetone [8,9]. [3H]Okadaic acid was incubated with 
the cytosolic fraction for 2 h at 0°C. The incubation mixture 
was filtered on a GFK glass fiber filter with acetone cooled to 
- 78°C as described previously [8]. Non-specific binding was 
measured in the presence of 500-fold excess of unlabeled 
okadaic acid. Specific binding was calculated by subtracting 
non-specific binding from total binding. 
2.3. Isolation of a specific binding protein(s) of okadaic acid 
from the cytosolic fraction of mouse skin by DEAE- 
cellulose column chromatography 
The cytosolic fraction was prepared from the epidermis of the 
backs of 60 mice. The total supernatant, containing 140 mg pro- 
tein, was applied to a DEAE-cellulose column (2.6 x 25.0 cm) 
equilibrated with 50 mM Tris-HCl buffer, pH 7.4, containing 
2 mM 2-mercaptoethanol, 2 mM EDTA, 2 mM EGTA, 
0.2 mM phenylmethanesulfonyl fluoride (PMSF), 0.2 mM leu- 
peptin and 10% glycerol. The fractions of eluate were tested for 
ability to bind 13H]okadaic acid specifically. 
3. RESULTS AND DISCUSSION 
3.1. Specific binding of fH]okadaic acid 
The specific binding of [3H]okadaic acid to the 
particulate fraction increased linearly with increase 
in protein concentration (fig. IA). With 200 /cg of 
protein of the particulate fraction, the specific 
binding of [3H]okadaic acid became saturated at 
about 80 nM [‘Hlokadaic acid (fig.lB). These 
results demonstrate the specific binding of [3H]- 
okadaic acid to the particulate fraction of mouse 
epidermis. Scatchard analysis of the equilibrium 
binding data (fig.lB, inset) indicated that the 
dissociation constant, KD, was 21.7 nM and the 
maximum binding capacity, B,,,, was 
2.5 pmol/mg protein. Unlabeled okadaic acid 
caused dose-dependent inhibition of the specific 
binding of [‘Hlokadaic acid to the particulate frac- 
tion (fig.2). The concentration of okadaic acid for 
50% inhibition, EDSO, was 30 nM. Okadaic acid 
tetramethyl ether, which is an inactive compound 
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Fig. 1. Specific binding of [3H]okadaic acid to the particulate 
fraction. Various concentrations of the particulate fraction were 
analysis [ 141. 
incubated with 80 nM [3H]okadaic acid (A) and 200 gg of the 
particulate fraction was incubated with various concentrations 
of [3H]okadaic acid (B). Total bound [‘Hlokadaic acid (TB, 
0), specifically bound [3H]okadaic acid (SB, l ) and non- 
specifically bound [“Hlokadaic acid (NSB, x). (Inset) Scatchard 
[7], did not inhibit the specific binding of [3H]- 
okadaic acid at concentrations of up to 1OOpM 
(fig.2). The specific binding of [3H]okadaic acid 
was also not inhibited by TPA-type tumor pro- 
moters, TPA or teleocidin (fig.2), or by the non- 
TPA type tumor promoters palytoxin and thap- 
sigargin (data not shown), which do not bind to the 
phorbol ester receptor [3,11], at concentrations of 
J 
Concentratmn ( nM ) 
Fig.2. Inhibition of specific binding of [‘Hlokadaic acid to the 
particulate fraction by various compounds. A mixture of 150 pg 
of the particulate fraction and 30 nM [“Hlokadaic acid was in- 
cubated with various concentrations of unlabeled okadaic acid 
(o), okadaic acid tetramethyl ether (0), TPA (x) or teleocidin 
(m). 
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up to 100 /cM. These results clearly indicated that 
the binding of t3H]okadaic acid is highly specific 
and that the specificity correlates well with the bio- 
logical activities of okadaic acid class tumor pro- 
moters. 
The specific binding of [3H]okadaic acid to a 
cytosolic fraction of mouse epidermis was also 
demonstrated (fig.3). The KD for binding was 
1.0 nM and the B,, was 6.8 pmol/mg protein. 
Scatchard analysis (fig.3B, inset) indicated that 
receptors in the cytosolic fraction appeared to have 
higher affinity for binding than those in the par- 
ticulate fraction. It is unknown how the binding of 
okadaic acid to the cytosolic fraction is related to 
its binding to the particulate fraction. We deter- 
mined the specific binding of [3H]okadaic acid per 
mg of these fractions of various mouse tissues 
(table 1). Both the particulate and cytosolic frac- 
tions of various mouse tissues, such as brain, lung, 
and colon showed specific binding, and the total 
amount of the binding molecule(s) seemed to be 
greater in the cytosolic fractions than in the par- 
ticulate fractions. If there are several binding 
molecules with different binding affinities of [3H]- 
okadaic acid in particulate and cytosolic fractions, 
the amounts of the binding molecule(s) of various 
tissues, as shown in table 1, might not indicate the 
exact total amount of binding molecule(s). But we 
thought that the cytosolic fraction contained a 
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Fig.3. Specific binding of [‘Hlokadaic acid to the cytosolic frac- 
tion. Various concentrations of the cytosolic fraction were in- 
cubated with 20 nM [‘Hlokadaic acid (A) and 15Opg of the 
cytosolic fraction was incubated with various concentrations of 
[‘Hlokadaic acid (B). Total bound [‘Hlokadaic acid (TB, 0), 
specifically bound [‘Hlokadaic acid (SB, l ) and nonspecifically 
bound [“Hlokadaic acid (NSB, x). (Inset) Scatchard analysis. 
Table 1 
Specific [‘Hlokadaic acid binding to fractions of various mouse 
tissues 
Specific [3H]okadaic acid binding to 
Particulate fractiona Cytosolic fractionb 
(pmol/mg protein) (pmol/mg protein) 
Brain 2.6 16.6 
Lung 2.3 7.8 
Colon 1.9 12.7 
Kidney 1.7 5.6 
Stomach 1.3 10.5 
Thymus 1.2 9.9 
Skin 1.1 9.2 
Spleen 1.1 8.1 
Ovaries 0.8 13.3 
Small intestine 0.7 18.5 
Liver 0.6 6.8 
a The particulate fraction (150 fig) was incubated with 80 nM 
[3H]okadaic acid. Specific binding of [3H]okadaic acid was 
measured by the filtration method with the buffer as described 
in the text 
b The cytosolic fraction (150rg) was incubated with 40 nM 
[‘Hlokadaic acid. Specific binding of [‘Hlokadaic acid was 
measured by the filtration method with cold acetone as 
described in the text 
Tissue was homogenized in 50 mM Tris-HCl buffer, pH 7.4, 
containing 10 mM EDTA, 2 mM EGTA and 0.2 mM PMSF by 
Polytron homogenizer for 1 min. The homogenate was cen- 
trifuged at 1000 x g for 30 min at 4°C. The supernatant was 
separated into cytosolic and particulate fractions by centrifuga- 
tion at 100000 x g for 60 min at 4°C 
larger amount of binding molecule(s) for [3H]- 
okadaic acid than did the particulate fraction. 
Therefore we have isolated the binding molecule(s) 
from a cytosolic fraction of mouse skin. 
3.2. Isolation of specific binding protein(s) of 
okadaic acid from the cytosolic fraction of 
mouse skin 
It was applied to DEAE-cellulose column 
chromatography to isolate the binding molecule(s). 
As seen in fig.4, one peak of material eluted with 
0.2 M NaCl showed high specific binding of [3H]- 
okadaic acid. We also found phosphatase activity 
and protein kinase activity in the binding fraction 
of mouse skin, and that the phosphatase activity 
was inhibited by okadaic acid (data not shown). 
Similar results have been found in mouse brain [5]. 
Based on our evidence that [3H]okadaic acid does 
not bind to the protein kinases contained in the 
binding fraction, the protein phosphatases seem to 
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Fig.4. DEAE-cellulose column chromatography of a cytosolic 
fraction of mouse epidermis. Material was eluted with 450 ml 
equilibrating buffer at 60 ml/h and then with the same buffer 
containing different concentrations of NaCl as follows, 320 ml 
of 0.1 M NaCl, 480 ml of 0.2 M NaCI, gradient (200 ml of 
0.2 M NaCl-200 ml of 1.0 M NaCl). 4 ml fractions were col- 
lected. Specific binding of each fraction (50 ~1) was measured 
with 10 nM [‘Hlokadaic acid. 
be binding molecules (receptors) for the okadaic 
acid class of tumor promoters (manuscript in 
preparation). Recently, it has been reported that 
okadaic acid inhibits protein phosphatase 1 and 
2A, but not protein phosphatase 2B [12,13]. We 
are now isolating protein phosphatase 1 and 2A 
and trying to study the direct binding of [3H]- 
okadaic acid to protein phosphatase 1and 2A. Pro- 
tein phosphatases are contained in larger amounts 
in brain than in other tissues. This fact is compati- 
ble with the results that brain contained a larger 
amount of the binding molecule(s) for [3H]okadaic 
acid than other tissues. 
Recently, we found calyculin A to be an addi- 
tional tumor promoter of the okadaic acid class, 
which was screened by the inhibition of the specific 
binding of [3H]okadaic acid to a particulate frac- 
tion (manuscript in preparation). This binding 
assay is useful to find further compounds of the 
okadaic acid class. These findings suggest he ex- 
istence of a new pathway of tumor promotion 
other than by activation of protein kinase C, the 
so-called phorbol ester receptor pathway. 
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